person

Nicolai T.

Country
Germany
Department
NA

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
210
Sites with multiple studies

Has run more than one trial at 210 of 450 partner sites.

Specializations

Inflammatory Skin Conditions

The investigator specializes in treating severe inflammatory dermatological conditions, with particular emphasis on hidradenitis suppurativa. Their research involves evaluating novel therapeutic approaches including lutikizumab and povorcitinib for managing moderate to severe cases.

  • Hidradenitis Suppurativa Management
  • Chronic Hand Eczema Treatment
  • Plaque Psoriasis Therapies

Their work extends to investigating topical treatments like ruxolitinib cream for chronic hand eczema and comparative studies of risankizumab for plaque psoriasis.

Chronic Wound Care

The investigator focuses on advanced therapeutic solutions for chronic venous ulcers, exploring innovative stem cell-based treatments and novel topical applications for therapy-resistant cases.

  • Venous Ulcer Treatment
  • Stem Cell Therapy Applications
  • Wound Healing Assessment

Their research includes evaluating the efficacy of allo-APZ2-CVU for improving wound closure in patients with treatment-resistant ulcers.

Dermatological Disorders

The investigator conducts research in various dermatological conditions, including vitiligo and skin candidiasis. Their work encompasses both systemic and topical treatment approaches.

  • Vitiligo Management
  • Skin Candidiasis Treatment
  • Topical Therapy Development

Their expertise includes evaluating long-term treatment outcomes in nonsegmental vitiligo and investigating new therapeutic options for inflammatory skin conditions.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.